Ipsen SA IPN
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPN is a good fit for your portfolio.
News
-
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
-
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
-
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
-
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
-
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
-
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
-
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
-
U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease
Trading Information
- Previous Close Price
- €112.30
- Day Range
- €111.10–114.40
- 52-Week Range
- €99.70–130.70
- Bid/Ask
- €112.50 / €112.70
- Market Cap
- €9.30 Bil
- Volume/Avg
- 24,535 / 77,072
Key Statistics
- Price/Earnings (Normalized)
- 10.93
- Price/Sales
- 2.84
- Dividend Yield (Trailing)
- 1.07%
- Dividend Yield (Forward)
- 1.07%
- Total Yield
- 1.07%
Company Profile
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 5,325
- Website
- https://www.ipsen.com
Competitors
Valuation
Metric
|
IPN
|
EXEL
|
UCB
|
---|---|---|---|
Price/Earnings (Normalized) | 10.93 | 25.86 | 26.18 |
Price/Book Value | 2.43 | 3.11 | 2.57 |
Price/Sales | 2.84 | 4.09 | 4.52 |
Price/Cash Flow | 12.22 | 21.56 | 25.94 |
Price/Earnings
IPN
EXEL
UCB
Financial Strength
Metric
|
IPN
|
EXEL
|
UCB
|
---|---|---|---|
Quick Ratio | 0.78 | 3.13 | 0.84 |
Current Ratio | 1.17 | 3.34 | 1.32 |
Interest Coverage | 40.25 | — | 3.88 |
Quick Ratio
IPN
EXEL
UCB
Profitability
Metric
|
IPN
|
EXEL
|
UCB
|
---|---|---|---|
Return on Assets (Normalized) | 12.69% | 9.47% | 5.10% |
Return on Equity (Normalized) | 21.64% | 11.88% | 8.82% |
Return on Invested Capital (Normalized) | 19.82% | 8.36% | 7.41% |
Return on Assets
IPN
EXEL
UCB
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Ypxlnkngh | Ypgkk | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Pfcvnqlxyj | Vlh | $68.9 Bil | |
HLN
| Haleon PLC ADR | Dwwktxvzw | Ydb | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Dsljzcyyb | Wfbx | $14.7 Bil | |
VTRS
| Viatris Inc | Wjnrnklkw | Kgwk | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Pdvzczpb | Mrgxy | $11.9 Bil | |
CTLT
| Catalent Inc | Dxfhpxfsx | Gpynmc | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Hpsbmwqc | Hdpn | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Pnjnygx | Xyyl | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Prfjlzk | Cbvtkq | $3.5 Bil |